newsfilter
← Latest News
Business Wire·

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the